This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kiniwa, Y. Articles by Kawakami, Y. Search for Related Content PubMed PubMed Citation Articles by Kiniwa, Y. Articles by Kawakami, Y.

Tumor Antigens Isolated from a Patient with Vitiligo and T-Cell-infiltrated Melanoma¹

Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine [Y. Ki., T. F., M. A., K. I., T. Sh., Y. S., Y. Ka.], Department of Dermatology, Shinshu University School of Medicine [Y. Ki., T. Sa.], Department of Dermatology, National Cancer Center Hospital [A. Y.], Shinjuku-ku, Tokyo 160-8582, Japan

Serological identification of tumor antigens by cDNA expression cloning is a technique used to isolate cDNAs encoding tumor antigens that are recognized by IgG antibodies in sera from cancer patients. It is also useful for the isolation of tumor antigens recognized by T cells. We applied this method to identify melanoma antigens recognized by the serum from a patient with a good prognosis who had T-cell-infiltrated melanoma and vitiligo. By screening a phage cDNA library constructed from a highly pigmented melanoma cell line, SKmel23, with the patient’s serum, 50 positive cDNA clones consisting of 26 distinct antigens were isolated. Of these, 20 encoded known proteins, and 6 encoded previously uncharacterized ones. The most frequently isolated clone, which we named KU-MEL-1, was unknown previously but was homologous to partial cDNA sequences registered in the expressed sequence tag database. Reverse transcription-PCR and Northern blot analysis demonstrated that KU-MEL-1 was strongly expressed in most melanoma cell lines, melanoma tissue samples, and cultured melanocytes and weakly expressed in cell lines derived from other types of tumors, as well as in some normal tissues, including testis. Western blot analysis with polyclonal murine antibody generated by immunization with the recombinant KU-MEL-1 protein demonstrated that the KU-MEL-1 protein was preferentially expressed in melanoma cells and melanocytes. IgG antibodies against KU-MEL-1 were detected in the sera from 9 of 26 melanoma patients and from some patients with other cancers, including brain tumor, esophageal cancer, colon cancer, and chronic myelogenous leukemia, but were not detected in sera from 30 healthy individuals. Although the IgG specific for KU-MEL-1 was not detected in sera from 12 vitiligo patients, it was detected in sera from 7 of 11 patients with Vogt-Koyanagi-Harada disease that is thought to be an autoimmune disease against melanocytes. These results suggest that KU-MEL-1 may be a useful target for the development of diagnostic and therapeutic methods for patients with various cancers, particularly with melanoma, as well as patients with autoimmune diseases against melanocytes.

This article has been cited by other articles:

				E. Hayashi, Y. Matsuzaki, G. Hasegawa, T. Yaguchi, S. Kurihara, T. Fujita, T. Kageshita, M. Sano, and Y. Kawakami Identification of a Novel Cancer-Testis Antigen CRT2 Frequently Expressed in Various Cancers Using Representational Differential Analysis Clin. Cancer Res., November 1, 2007; 13(21): 6267 - 6274. [Abstract] [Full Text] [PDF]

				S. Sugita, H. Takase, C. Taguchi, Y. Imai, K. Kamoi, T. Kawaguchi, Y. Sugamoto, Y. Futagami, K. Itoh, and M. Mochizuki Ocular Infiltrating CD4+ T Cells from Patients with Vogt-Koyanagi-Harada Disease Recognize Human Melanocyte Antigens. Invest. Ophthalmol. Vis. Sci., June 1, 2006; 47(6): 2547 - 2554. [Abstract] [Full Text] [PDF]

				S Otani, T Sakurai, K Yamamoto, T Fujita, Y Matsuzaki, Y Goto, Y Ando, S Suzuki, M Usui, M Takeuchi, et al. Frequent immune response to a melanocyte specific protein KU-MEL-1 in patients with Vogt-Koyanagi-Harada disease Br J Ophthalmol, June 1, 2006; 90(6): 773 - 777. [Abstract] [Full Text] [PDF]

				Y. Goto, Y. Matsuzaki, S. Kurihara, A. Shimizu, T. Okada, K. Yamamoto, H. Murata, M. Takata, H. Aburatani, D. S.B. Hoon, et al. A new melanoma antigen Fatty Acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy. Cancer Res., April 15, 2006; 66(8): 4443 - 4449. [Abstract] [Full Text] [PDF]

				T. Okada, M. Akada, T. Fujita, T. Iwata, Y. Goto, K. Kido, T. Okada, Y. Matsuzaki, K. Kobayashi, S. Matsuno, et al. A Novel Cancer Testis Antigen That Is Frequently Expressed in Pancreatic, Lung, and Endometrial Cancers Clin. Cancer Res., January 1, 2006; 12(1): 191 - 197. [Abstract] [Full Text] [PDF]

				M Kitamura, N Kitaichi, M Takeuchi, H Kitamei, K Namba, S-i Yamagishi, K Iwabuchi, K Onoe, and S Ohno Decrease in the glyceraldehyde derived advanced glycation end products in the sera of patients with Vogt-Koyanagi-Harada disease Br J Ophthalmol, November 1, 2005; 89(11): 1407 - 1409. [Abstract] [Full Text] [PDF]

				T. Iwata, T. Fujita, N. Hirao, Y. Matsuzaki, T. Okada, H. Mochimaru, N. Susumu, E. Matsumoto, K. Sugano, N. Yamashita, et al. Frequent Immune Responses to a Cancer/Testis Antigen, CAGE, in Patients with Microsatellite instability-Positive Endometrial Cancer Clin. Cancer Res., May 15, 2005; 11(10): 3949 - 3957. [Abstract] [Full Text] [PDF]

				T. Ishikawa, T. Fujita, Y. Suzuki, S. Okabe, Y. Yuasa, T. Iwai, and Y. Kawakami Tumor-specific Immunological Recognition of Frameshift-mutated Peptides in Colon Cancer with Microsatellite Instability Cancer Res., September 1, 2003; 63(17): 5564 - 5572. [Abstract] [Full Text] [PDF]

				J. Fodor, Y. Kawakami, and Y. Kiniwa Correspondence re: Y. Kiniwa et al., Tumor Antigens Isolated from a Patient with Vitiligo and T-Cell-infiltrated Melanoma. Cancer Res., 61: 7900-7907, 2001. Cancer Res., August 15, 2002; 62(16): 4836 - 4837. [Full Text] [PDF]